24/7 Market News Snapshot 24 June, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)

June 24, 2025

DENVER, Colo., 24 June, 2025 (www.247marketnews.com) – (Nasdaq:PSTV) are discussed in this article.
Plus Therapeutics, Inc. (Nasdaq:PSTV), a pioneering clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for challenging central nervous system (CNS) cancers, has experienced significant market activity, currently trading at $0.225 after a notable rise of 22.08% from the previous close. This surge is indicative of growing investor confidence, supported by a trading volume of 49.78 million shares, highlighting heightened interest in the company’s financial outlook and prospects.

In a strategic development, Plus Therapeutics has announced a major restructuring of its previously disclosed $15 million equity financing, aimed at bolstering shareholder value and refining its equity capital structure. The restructuring effectively eliminates the potential issuance of approximately 1.5 billion shares of common stock, with a key highlight being the removal of dilutive warrants associated with the equity financing. Consequently, only around 36 million shares will remain available for issuance through the newly amended Series B Warrants, which now feature a more favorable cashless exercise ratio.

Additionally, this initiative includes the cancellation of around 25 million shares of common stock, thereby further reducing potential dilution for existing shareholders. The Company has committed to allocating 90% of any future capital raised after July 1, 2025, towards repaying holders of 22,727,270 shares of common stock at 115% of their original purchase price.

As Plus Therapeutics moves forward, it continues to advance its innovative product candidates focused on treating leptomeningeal metastases and recurrent glioblastoma through groundbreaking drug delivery techniques. The Company expresses gratitude to all parties involved in this restructuring, which is essential for positioning Plus Therapeutics for sustained growth and operational clarity as it seeks to revolutionize therapies for patients with difficult-to-treat cancers.

Related news for (PSTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.